4/17
08:48 am
eols
Evolus, Inc. (NASDAQ: EOLS) is now covered by analysts at BTIG Research. They set a "buy" rating and a $21.00 price target on the stock.
Medium
Report
Evolus, Inc. (NASDAQ: EOLS) is now covered by analysts at BTIG Research. They set a "buy" rating and a $21.00 price target on the stock.
4/16
08:34 am
eols
Evolus Announces Commercial Launch of Evolysse™ [Yahoo! Finance]
Low
Report
Evolus Announces Commercial Launch of Evolysse™ [Yahoo! Finance]
4/16
08:00 am
eols
Evolus Announces Commercial Launch of Evolysse™
Low
Report
Evolus Announces Commercial Launch of Evolysse™
4/15
08:17 am
eols
Evolus Launches "Drop the F Word" Campaign in Advance of the Commercial Launch of Evolysse™ Injectable Hyaluronic Acid Gels [Yahoo! Finance]
Low
Report
Evolus Launches "Drop the F Word" Campaign in Advance of the Commercial Launch of Evolysse™ Injectable Hyaluronic Acid Gels [Yahoo! Finance]
4/15
08:00 am
eols
Evolus Launches “Drop the F Word” Campaign in Advance of the Commercial Launch of Evolysse™ Injectable Hyaluronic Acid Gels
Low
Report
Evolus Launches “Drop the F Word” Campaign in Advance of the Commercial Launch of Evolysse™ Injectable Hyaluronic Acid Gels
4/10
08:49 am
eols
Evolus, Inc. (NASDAQ: EOLS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $27.00 price target on the stock.
High
Report
Evolus, Inc. (NASDAQ: EOLS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $27.00 price target on the stock.
4/9
08:09 am
eols
Evolus, Inc. (NASDAQ: EOLS) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $22.00 price target on the stock.
High
Report
Evolus, Inc. (NASDAQ: EOLS) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $22.00 price target on the stock.
3/25
08:00 am
eols
Evolus to Participate in The Needham 24th Annual Virtual Healthcare Conference
Medium
Report
Evolus to Participate in The Needham 24th Annual Virtual Healthcare Conference
3/24
08:07 pm
eols
AEON Biopharma Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update [Yahoo! Finance]
Medium
Report
AEON Biopharma Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update [Yahoo! Finance]
3/21
04:05 pm
eols
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
3/5
08:11 am
eols
Evolus, Inc. (NASDAQ: EOLS) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $22.00 price target on the stock.
Low
Report
Evolus, Inc. (NASDAQ: EOLS) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $22.00 price target on the stock.
3/5
08:11 am
eols
Evolus, Inc. (NASDAQ: EOLS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $27.00 price target on the stock.
Low
Report
Evolus, Inc. (NASDAQ: EOLS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $27.00 price target on the stock.
3/5
08:11 am
eols
Evolus, Inc. (NASDAQ: EOLS) had its price target raised by analysts at Barclays PLC from $22.00 to $25.00. They now have an "overweight" rating on the stock.
Low
Report
Evolus, Inc. (NASDAQ: EOLS) had its price target raised by analysts at Barclays PLC from $22.00 to $25.00. They now have an "overweight" rating on the stock.
3/4
04:45 pm
eols
Evolus Reports Record Fourth Quarter and Full-Year 2024 Financial Results; Reaffirms 2025 Guidance [Yahoo! Finance]
Medium
Report
Evolus Reports Record Fourth Quarter and Full-Year 2024 Financial Results; Reaffirms 2025 Guidance [Yahoo! Finance]
3/4
04:05 pm
eols
Evolus Reports Record Fourth Quarter and Full-Year 2024 Financial Results; Reaffirms 2025 Guidance
Low
Report
Evolus Reports Record Fourth Quarter and Full-Year 2024 Financial Results; Reaffirms 2025 Guidance
2/27
08:32 am
eols
Evolus to Participate in Fireside Chats and One-on-One Meetings at Upcoming Investor Conferences [Yahoo! Finance]
Medium
Report
Evolus to Participate in Fireside Chats and One-on-One Meetings at Upcoming Investor Conferences [Yahoo! Finance]
2/27
08:00 am
eols
Evolus to Participate in Fireside Chats and One-on-One Meetings at Upcoming Investor Conferences
Medium
Report
Evolus to Participate in Fireside Chats and One-on-One Meetings at Upcoming Investor Conferences
2/24
03:35 pm
eols
AEON Biopharma, Inc. Announces Reverse Stock Split [Yahoo! Finance]
Low
Report
AEON Biopharma, Inc. Announces Reverse Stock Split [Yahoo! Finance]
2/20
08:51 am
eols
Evolus to Participate in the TD Cowen 2nd Annual Glowing Ahead: Beauty & Wellness Summit [Yahoo! Finance]
Low
Report
Evolus to Participate in the TD Cowen 2nd Annual Glowing Ahead: Beauty & Wellness Summit [Yahoo! Finance]
2/20
08:00 am
eols
Evolus to Participate in the TD Cowen 2nd Annual Glowing Ahead: Beauty & Wellness Summit
Medium
Report
Evolus to Participate in the TD Cowen 2nd Annual Glowing Ahead: Beauty & Wellness Summit
2/18
08:32 am
eols
Evolus to Report Fourth Quarter and Year End 2024 Results on March 4, 2025 [Yahoo! Finance]
Low
Report
Evolus to Report Fourth Quarter and Year End 2024 Results on March 4, 2025 [Yahoo! Finance]
2/18
08:00 am
eols
Evolus to Report Fourth Quarter and Year End 2024 Results on March 4, 2025
Low
Report
Evolus to Report Fourth Quarter and Year End 2024 Results on March 4, 2025
2/14
08:07 am
eols
Evolus, Inc. (NASDAQ: EOLS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $27.00 price target on the stock.
Low
Report
Evolus, Inc. (NASDAQ: EOLS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $27.00 price target on the stock.
2/13
02:07 pm
eols
Evolus wins approval for hyaluronic acid dermal fillers [Seeking Alpha]
Low
Report
Evolus wins approval for hyaluronic acid dermal fillers [Seeking Alpha]
2/13
01:57 pm
eols
Evolus Announces FDA Approval of Evolysse™ Form and Evolysse™ Smooth Injectable Hyaluronic Acid Gels [Yahoo! Finance]
Medium
Report
Evolus Announces FDA Approval of Evolysse™ Form and Evolysse™ Smooth Injectable Hyaluronic Acid Gels [Yahoo! Finance]